Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma

Li, Jinghui; Liu, Xiaoyu; Qiao, Yu; Qi, Renli; Liu, Shun-Jin; Guo, Jing; Gui, Yang; Li, Juanjuan; Yu, Hualin

doi:10.3389/fonc.2018.00413

Cited by 5 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioma, a common intracranial malignant tumor of the human central nervous system, is highly invasive and has poor prognosis. 33 BBB and BBTB are the biggest obstacles that hamper the delivery of several drugs to gliomas, thus limiting their efficacy. 34 , 35 Development and discovery of novel and efficient drug delivery systems that can traverse the BBB and target the intracranial tumors are highly desired for the treatment of malignant glioma.…”

Section: Discussionmentioning

confidence: 99%

Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

Wu¹,

Li²,

Deng³

et al. 2021

IJN

View full text Add to dashboard Cite

Purpose Cell membrane-camouflaged nanoparticles (NPs) are drawing increasing attention because their surfaces acquire some characteristics of the cell membranes, making them a unique class of biomimetic materials for diverse applications. Modification of cell membrane or combination of different types of membranes can enhance their functionality. Methods We prepared platelet and tumor cell membrane camouflaged β-mangostin-loaded NPs, which were synthesized with platelet–C6 hybrid biomimetic coating, poly(lactic-co-glycolic acid), and β-mangostin (β-PCNPs). Then, we evaluated their targeting ability and anticancer activity against glioma in vitro and in vivo. Results Biomimetic coating enhanced active drug targeting and immune escape properties of nanocarrier in C6 and THP-1 cells, respectively, which improved their cytotoxicity. β-PCNPs were characterized to study the inherent properties of both source cells. Compared with bare β-NPs, β-PCNPs exhibited high tumor-targeting capability and induced apoptosis of C6 cells in vitro. Similarly, intravenous administration of drug through β-PCNPs resulted in enhanced tumor-targeting and exhibited excellent rate of inhibition of glioma tumor growth in mice. Moreover, the blood circulation time of drug in mice in the β-PCNP group was markedly prolonged and these mice exhibited better outcome than those in the β-NP group. Conclusion These results provide a new strategy of utilizing PCNPs as carriers for drug delivery, which improves the targeting efficiency and therapeutic efficacy of chemotherapeutic agents for glioma therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

Wu¹,

Li²,

Deng³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Glioma, a common intracranial malignant tumor of the human central nervous system, is highly invasive and has poor prognosis [30] . BBB and BBTB are the biggest obstacles that hamper the delivery of several drugs, thus limiting their e cacy against glioma [31 32] .…”

Section: Discussionmentioning

confidence: 99%

Platelet–Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

Deng

et al. 2021

Preprint

View full text Add to dashboard Cite

Cell membrane-camouflaged nanoparticles are drawing increasing attention because their surfaces retain the natural functionalities of the cell plasma membranes, making them a unique class of biomimetic materials combining natural and synthetic components. Modifying the cell membranes or combining the functions of different types of membranes enhances their functionality. Herein, we prepared platelet and tumor cell membrane camouflaged antitumor nanoparticles. The effects of β-mangostin-loaded nanoparticles on the target and its anticancer action in glioma were measured in vitro and in vivo. Multifunctional nanoparticles were manufactured with platelet–C6 hybrid biomimetic coating (PCM), lactic-co-glycolic acid (PLGA), and β-mangostin. PCM increased the proportion of active drug targeting in C6 and immune escape characteristics in THP-1 cells, thus enhancing the cytotoxicity of β-PCNPs. The β-PCNPs were comprehensively characterized to study the inherent properties of both source cells. Compared with bare β-NPs, β-PCNPs exhibited high tumor-targeting ability and induced apoptosis of C6 cells in vitro. Mice experiments with intravenous administration of the drug revealed that the β-PCNP platform enhanced the tumor targeting capability and exhibited excellent chemotherapy with high inhibition rate of glioma tumor growth in vivo. The mice in the β-PCNP group had a markedly prolonged circulation lifetime and exhibited better outcome than those in the β-NP group. These results provide a new strategy of utilizing PCNPs as carriers for drug delivery, which improves the targeting efficiency and therapeutic efficacy of chemotherapeutic agents for glioma therapy.

show abstract

“…These studies suggest that the effect of TP53 rs1042522 C>G polymorphism on glioma risk is strongly associated with glioma subtype, genetic factors, and age. In separate analyses based on the association of TP53 rs1042522 C>G polymorphism with glioma risk in different national populations, TP53 rs1042522 C>G polymorphism was significantly associated with glioma risk in patients with gliomas in India and China [43][44][45]. In contrast, no association was found in patients from Portugal and Brazil [46,47], and these studies mainly focused on predominantly adults.…”

Section: Biomed Research Internationalmentioning

confidence: 99%

Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children

Liao

Zhu

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Glioma is the most common intracranial malignancy. TP53 is a crucial tumor suppressor gene that plays an essential regulatory role in cell growth, apoptosis, and DNA repair. The TP53 rs1042522 C>G polymorphism has been reported to be strongly associated with various tumor risks. To assess the TP53 rs1042522 C>G polymorphism with glioma risk in Chinese children, we determined the genotypes of the TP53 rs1042522 C>G polymorphism in 171 glioma patients and 228 cancer-free controls by Taqman assay. We assessed the association of the polymorphism with glioma risk using odds ratio (OR) and 95% confidence interval (CI) generated by logistic regression models. We also performed stratified analyses by age, gender, tumor subtypes, and clinical stages, but no significant association was detected between TP53 rs1042522 C>G polymorphism and childhood glioma risk. These results suggest that the TP53 rs1042522 C>G polymorphism is not associated with glioma risk in Chinese children. Subsequent studies with a larger sample size are needed to validate our results.

show abstract

Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma

Cited by 5 publications

References 36 publications

Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

Platelet–Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children

Contact Info

Product

Resources

About